At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 205 enrolled
Drug / intervention
adalimumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein
In Brief
A Phase 3 clinical trial evaluating adalimumab and placebo for Crohn's Disease. Completed, enrolled 205 participants.
Detailed Summary
This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease in China.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartAug 2015
Primary CompletionMay 2017
Study CompletionDec 2017
TodayJul 2026
First PostedJul 16, 2015
Enrollment StartAug 17, 2015
Primary CompletionMay 19, 2017
Study CompletionDec 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.0 years ago
Interventions
adalimumabbiological
subcutaneous injections of adalimumab
placeboother
subcutaneous injections of placebo